Liquidia Technologies, Inc.
(NASDAQ : LQDA)

( )
LQDA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.82%33.750.9%$1145.03m
JNJJohnson & Johnson 0.29%143.270.7%$1079.06m
BMYBristol-Myers Squibb Co. -1.19%59.571.0%$967.54m
MRKMerck & Co., Inc. -1.07%77.880.7%$816.26m
ABBVAbbVie, Inc. -0.03%99.322.3%$785.33m
LLYEli Lilly & Co. 1.42%169.121.1%$695.99m
AZNAstraZeneca Plc 1.35%54.191.2%$290.07m
VXRTVaxart, Inc. -8.12%8.150.0%$286.48m
RPRXRoyalty Pharma Plc 2.06%48.020.1%$226.50m
NVSNovartis AG 0.36%88.120.2%$151.51m
RGENRepligen Corp. 0.92%125.287.2%$117.23m
GSKGlaxoSmithKline Plc 0.84%40.720.2%$112.42m
NVONovo Nordisk A/S 1.25%65.870.1%$94.18m
RETAReata Pharmaceuticals, Inc. 1.52%158.003.4%$82.12m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 8.02%77.860.0%$73.21m

Company Profile

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.